Should COVID-19 Vaccines Be Made Available Through Expanded Access?
As more encouraging data on COVID-19 vaccines is released, companies are applying for Emergency Use Authorizations (EUAs) from the FDA. However, there is concern that issuing EUAs to these vaccines at their current stage of development would not require full reporting of adverse events, and could hinder current and ongoing trials. Some believe that authorizing and distributing COVID-19 vaccines through Expanded Access is a better option, as this method would facilitate access to those at greatest risk, while preserving the integrity of ongoing large-scale clinical trials.
Companies are applying for Emergency Use Authorizations for COVID-19 vaccines, but some think the Expanded Access pathway will better preserve the integrity of ongoing trials. Are you for or against approving COVID-19 vaccines through Expanded Access?

Last Answered: 6 days ago